View Older Stories View More Recent Stories

Feb 28, 2017 01:00PM Recent Survey Finds Many Adults with Diabetes Unaware of Their Increased Risk for Certain Serious Illnesses
Feb 26, 2017 12:30PM Merck’s Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in Bone Marrow Transplant Recipients, Highly Effective Through Week 24 Post-Transplant in
Feb 24, 2017 04:02PM Merck (MRK) Says V212 Reduced Incidence of Confirmed HZ Cases in First Phase 3 Trial
Feb 24, 2017 04:00PM In First Phase 3 Trial, Merck’s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromis
Feb 23, 2017 11:33AM Trump again vows to bring back U.S. jobs, but offers few details
Feb 20, 2017 08:00AM Aptus Health's RxStart(TM) Solution Launches with Electronic Health Record Partners to Engage Providers and Patients at the Point of Care
Feb 16, 2017 08:00AM Merck’s Fight Against Infectious Disease Goes Digital with Launch of ILÚM Health Solutions
Feb 14, 2017 05:03PM Merck (MRK) Stops EPOCH Study of Verubecestat in Mild to Moderate AD on Lack of Efficacy
Feb 14, 2017 05:00PM Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer’s Disease to Stop for Lack of Efficacy
Feb 14, 2017 04:53PM Merck (MRK) Says Its Phase 3 Trial of Doravirine for HIV-1 Infection Met Primary Efficacy Endpoint
Feb 14, 2017 04:05PM Merck’s Doravirine, an Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV-1 Infection, Met Primary Efficacy Endpoint in Pivotal Phase 3 Trial
Feb 3, 2017 06:48AM Merck (MRK) Announces FDA Acceptance of Two sBLAs for KEYTRUDA
Feb 3, 2017 06:45AM FDA Accepts Two sBLAs for Merck’s KEYTRUDA® (pembrolizumab) for Locally Advanced or Metastatic Urothelial Cancer in Cisplatin-Ineligible First-Line and Second-Line Post-Platinum Failure Treatment S
Feb 2, 2017 06:45AM Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results
Jan 31, 2017 04:00PM European Commission Approves KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or
Jan 25, 2017 07:00AM Pro Football Hall of Famer and Cancer Survivor Jim Kelly Teams Up with Merck and Leading Cancer Organizations to Launch Your Cancer Game Plan
Jan 20, 2017 04:02PM Bristol-Myers Squibb (BMY), Ono Enter Settlement and License Agreement with Merck (MRK) to Resolve PD-1 Antibody Patent Litigation
Jan 20, 2017 04:01PM Merck Announces Settlement and License Agreement Resolving KEYTRUDA® (pembrolizumab) Patent Litigation
Jan 20, 2017 04:01PM Bristol-Myers Squibb and Ono Pharmaceutical Company Enter Settlement and License Agreement with Merck to Resolve PD-1 Antibody Patent Litigation
Jan 20, 2017 07:24AM Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
Jan 19, 2017 01:30AM MSD for Mothers Commits $10 Million and Business Expertise to the Global Financing Facility to Help End Preventable Deaths of Mothers
Jan 18, 2017 09:00AM Merck Foundation Grant Expands Project ECHO® in Vietnam and India
Jan 10, 2017 04:08PM Merck (MRK) Announces FDA Accepts for Review the sBLA for KEYTRUDA; PDUFA Date May 10, 2017
Jan 10, 2017 04:06PM Merck Receives FDA Acceptance of Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Metastatic Non-Squamous Non-Smal
Jan 9, 2017 08:05AM Incyte (INCY), Merck (MRK) to Advance Clinical Development of Epacadostat with KEYTRUDA Combo
Jan 9, 2017 08:00AM Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA® (pembrolizumab)
Jan 6, 2017 08:00AM Merck to Participate at the 35th Annual J.P. Morgan Healthcare Conference
Jan 3, 2017 06:45AM Merck to Hold Fourth-Quarter and Full-Year 2016 Sales and Earnings Conference Call on February 2
Dec 19, 2016 07:01AM Merck (MRK) Announces KEYTRUDA Approval in Japan to Treat Advanced NSCLC
Dec 19, 2016 07:00AM KEYTRUDA® (pembrolizumab) Approved as First Anti-PD-1 Therapy in Japan for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express High Levels of PD-L1
Dec 16, 2016 07:28AM Merck (MRK) KEYTRUDA Gains Positive CHMP Recommendation for the First-Line Treatment of Patients with Metastatic NSCLC
Dec 16, 2016 07:26AM European Medicines Agency’s CHMP Recommends Merck’s KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD
Dec 12, 2016 07:01AM Merck (MRK) and Eisai Reports Encourating Phase 1b/2 KEYTRUDA/HALAVEN Combo Results
Dec 12, 2016 07:00AM Interim Results from Phase 1b/2 Study Evaluating the Combination of Merck’s KEYTRUDA® (pembrolizumab) and Eisai’s HALAVEN® (eribulin mesylate) Injection in Metastatic Triple-Negative Breast Canc
Dec 12, 2016 07:00AM Interim Results from Phase 1b/2 Study Evaluating the Combination of Merck's KEYTRUDA® (pembrolizumab) and Eisai's HALAVEN® (eribulin mesylate) Injection in Metastatic Triple-Negative Breast Cancer P
Dec 7, 2016 06:11AM Merck (MRK) Announces Positive HRQoL Data from KEYTRUDA Phase 3 KEYNOTE-024 Study
Dec 7, 2016 02:45AM KEYTRUDA® (pembrolizumab) Demonstrated Improved Health-Related Quality of Life Compared to Chemotherapy in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
Dec 6, 2016 09:00AM Merck's Consumer Health Business Drives Consumer-Centric, Purposeful Innovation
Dec 6, 2016 08:24AM Merck (MRK) Updates on KEYTRUDA Phase 1b KEYNOTE-028 Study; Clinical Activity, Durable Responses Observed
Dec 6, 2016 08:20AM Updated KEYTRUDA® (pembrolizumab) Data in Small Cell Lung Cancer and Mesothelioma Presented at 17th World Conference on Lung Cancer
Dec 6, 2016 08:00AM Merck to Participate at the Citi 2016 Global Healthcare Conference
Dec 6, 2016 06:21AM Merck (MRK) to Present Strong Results from Two KEYTRUDA Studies in r/r cHL
Dec 5, 2016 07:30PM KEYTRUDA® (pembrolizumab) Treatment Results in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Presented at 58th Annual Meeting of the American Society of Hematology
Dec 5, 2016 10:45AM Merck (MRK) KEYTRUDA Showed 41% ORR
Dec 5, 2016 10:42AM Updated KEYTRUDA® (pembrolizumab) Findings in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma Presented at 58th Annual Meeting of the American Society of Hematology
Dec 5, 2016 08:17AM Merck (MRK) Lists Cancer Genetics (CGIX) as KEYTRUDA National Reference Laboratory
Dec 1, 2016 07:07AM Merck's (MRK) sBLA for KEYTRUDA Accepted by U.S. FDA in r/r CHL
Dec 1, 2016 07:00AM FDA Grants Priority Review to Supplemental Biologics License Application (sBLA) for Merck’s KEYTRUDA® (pembrolizumab) in Relapsed or Refractory Classical Hodgkin Lymphoma
Nov 30, 2016 07:03AM Merck (MRK) to Present New KEYTRUDA Data at Upcoming Conference
Nov 30, 2016 07:00AM New KEYTRUDA® (pembrolizumab) Data to be Presented at 17th World Conference on Lung Cancer Highlight Research Across the Spectrum of Thoracic Malignancies
View More Recent Stories View Older Stories